Abivax (ABVX)

Executive Summary

Abivax is a clinical-stage biotechnology company developing novel therapies that modulate the immune system by targeting microRNA. Its lead candidate, obefazimod (ABX464), is being evaluated for moderately to severely active ulcerative colitis (UC). The company recently completed a Phase 3 trial (NCT05507203) in June 2025, which showed positive efficacy and safety data, positioning obefazimod as a potential first-in-class oral therapy for UC. Abivax is also conducting an additional Phase 3 study (NCT05177835) with an expected completion date in April 2026, which could further support the regulatory filing. Beyond UC, the company has a pipeline of 22 drug candidates in earlier stages, including programs in rheumatoid arthritis and viral infections, though none are as advanced as obefazimod. With a market capitalization around $8.6 billion, Abivax is a mid-cap biotech with significant upside potential if obefazimod receives regulatory approval.

Upcoming Catalysts (preview)

• Q2 2026Data readout from ongoing Phase 3 trial of obefazimod in UC (NCT05177835)75% success
• H2 2026Regulatory filing submissions (FDA/EMA) for obefazimod in UC60% success
• H1 2027Initiation of Phase 2 trials for next-generation pipeline candidates40% success